microRNA-155及microRNA-146a在慢性淋巴增殖性疾病中的表达及临床意义

The expression of microRNA-155 and microRNA-146a and its＇ clinical value in chronic lymphoproliferative disorders

目的观察microRNA-155及microRNA-146a在慢性淋巴细胞白血病（CLL）、套区细胞淋巴瘤（MCL）及脾脏边缘区淋巴瘤（SMZL）患者CD19^＋B淋巴细胞中的表达，并分析其临床意义。方法以53例CLL、13例MCL、9例SMZL患者和12名正常人为研究对象。取外周血（78份）或骨髓（9份），常规分离单个核细胞，并行CD19磁珠分选。提取CD19^＋细胞总RNA，应用TaqMan探针法检测microRNA-155及microRNA-146a的表达，结合患者临床资料进行统计学分析。结果①microRNA-155在CLL患者中的表达（4．49±0．83）显著高于MCL（3．83±0．45）及SMZL（3．80±0．61）（P〈0．05）；②SMZL患者中microRNA-146a的表达（3．81±0．59）显著高于CLL（2．58±0．90）及MCL（2．21±0．88）（P〈0．01）；③CLL Ig VH未突变组患者microRNA-155的表达显著高于突变组患者（P=0．012）；④CLL患者不同细胞遗传学分组间microRNA-155及microRNA-146a的表达差异元统计学意义（P〉0．05）。结论①不同慢性淋巴增殖性疾病（LPD）之间microRNA-155及microRNA．146a的表达存在差异；②提示microRNA可能与慢性LPD的发病甚至预后相关。

Objective To investigate the expression of microRNA-155 and microRNA-146a in the CD19^＋ B cells of chronic lymphocytic leukemia（ CLL）, mantle cell lymphoma（MCL） , splenic marginal zone lymphoma（ SMZL）, and to analyze its clinical significance. Methods Peripheral blood （PB） （78 cases） and bone marrow（BM） samples （9 cases） from 53 CLL patients, 13 MCL patients, 19 SMZL patients, and 12 healthy donors were collected. Mononuclear cells were isolated and B ceils were purified with a CD19^＋ magnetic-bead system. Total RNA was extracted from purified CD19^＋ cells and microRNAs expression were measured using the TaqMan microRNA quantitative PCR. The results combined with the clinic data of patients were analysed. Results （1）The expression of microRNA-155 in CLL（4.49 ± 0.83 ） was significantly higher than in MCL（3.83 ±0.45） and SMZL（3.80 ±0.61 ） （P 〈0.05） ;（2）The level of microRNA-146a in SMZL （3.81 ±0.59） was significantly higher than in CLL（2.58 ± 0.90） and MCL（2.27 ± 0.88 ） （P 〈 0.01 ） ; （3）The level of microRNA-155 was significantly higher in IgVH unmntated patients than in mutated patients in CLL（ P = 0. 012 ） ;（4）The microRNAs expression had no statistical difference between two prognostic groups in CLL. Conclusion （1）The expression of microRNA-155 and microRNA-146a is different in malignant lymphoproliferative disorders （LPD） ;（2）Deregulation of the microRNAs expression might play a critical role in the pathogenesis and prognosis in the LPD.